No evidence of disease activity including cognition (NEDA-3 plus) in naïve pediatric multiple sclerosis patients treated with natalizumab.

Monica MargoniFrancesca RinaldiAlice RiccardiSilvia FranciottaPaola PeriniPaolo Gallo

Published in: Journal of neurology (2019)

Early treatment of aggressive POMS with NTZ proved to be highly effective in achieving and maintaining the NEDA-3 plus status. Our data support the use of NTZ as first treatment choice in POMS.

Keyphrases

multiple sclerosis
disease activity
rheumatoid arthritis
systemic lupus erythematosus
rheumatoid arthritis patients
combination therapy
young adults
smoking cessation